Clinical and Molecular Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria.

Date publication

janvier 2023

Journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr PAGLIUCA Simona

Tous les auteurs :
Gurnari C, Pagliuca S, Prata PH, Galimard JE, Catto LFB, Larcher L, Sebert M, Allain V, Patel BJ, Durmaz A, Pinto AL, Inacio MCB, Hernandez L, Dhedin N, Caillat-Zucman S, Clappier E, Sicre de Fontbrune F, Voso MT, Visconte V, Peffault de Latour R, Soulier J, Calado RT, Socié G, Maciejewski JP

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36054881

Résumé

Secondary myeloid neoplasms (sMNs) remain the most serious long-term complications in patients with aplastic anemia (AA) and paroxysmal nocturnal hemoglobinuria (PNH). However, sMNs lack specific predictors, dedicated surveillance measures, and early therapeutic interventions.

Mots clés

Humans, Anemia, Aplastic, genetics, Hemoglobinuria, Paroxysmal, genetics, Retrospective Studies, Cross-Sectional Studies, Clonal Evolution, genetics

Référence

J Clin Oncol. 2023 01 1;41(1):132-142